Aurobindo Pharma has addressed recent trading volume increases in its securities, stating they are purely market-driven. The company confirms that all material information has been disclosed and there are no pending announcements that could affect the price or volume. The announcement follows media coverage of the potential impact of the Minimum Import Price (MIP) on Penicillin-G, and downstream derivatives where Lyfius Pharma Private Limited (a wholly owned subsidiary) is engaged.
Response to Trading Activity
Aurobindo Pharma has issued a statement regarding the recent increase in the trading volume of its securities. The company believes that the volume movement is primarily influenced by market dynamics and is not attributable to any undisclosed information.
Minimum Import Price (MIP) Impact
The company acknowledged media coverage concerning the potential impact of the Minimum Import Price (MIP) on Penicillin-G, 6-Aminopenicillanic Acid (6-APA) and Amoxicillin Trihydrate. These details were previously disclosed by the Government. Lyfius Pharma Private Limited, a wholly owned subsidiary, is involved in manufacturing Penicillin-G and its derivatives.
Disclosure Compliance
Aurobindo Pharma maintains that it is in full compliance with all disclosure obligations. The company reiterates that there is no undisclosed information that could specifically or exclusively influence the trading volume of its securities.
Source: BSE
